Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences

Rhea-AI Summary

Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology firm, announced its participation in two virtual investor conferences. The first will be at the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021, at 11:45 a.m. ET, featuring a fireside chat. The second event is at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 a.m. ET, with a corporate presentation. Live webcasts are available on the company's website and will be replayed for a limited time.

WILMINGTON, Del., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in two upcoming virtual investor conferences:

• Morgan Stanley 19^th Annual Global Healthcare Conference
  Fireside chat at 11:45 a.m. ET on Thursday, September 9, 2021

• H.C. Wainwright 23^rd Annual Global Investment Conference
  Corporate presentation at 7:00 a.m. ET on Monday, September 13, 2021

A live webcast of the Morgan Stanley fireside chat and H.C. Wainwright presentation can be accessed under “Events & Presentations” in the Investor Section of the Company’s website, https://investors.preludetx.com/news-and-events/events-and-presentations, where a replay of the events will also be available for a limited time.

About Prelude Therapeutics

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s lead product candidates are designed to be oral, potent, and selective inhibitors of PRMT5. Prelude’s first clinical candidate, PRT543, is in Phase 1 development for advanced solid tumors and select myeloid malignancies. Prelude is also advancing PRT811, a second PRMT5 inhibitor optimized for high brain exposure, in a Phase 1 clinical trial including glioblastoma multiforme (GBM). The Company’s pipeline also includes its third clinical candidate, PRT1419, an orally available MCL1 inhibitor in Phase 1 development for patients with relapsed/refractory hematologic malignancies, and its two most advanced preclinical candidates, PRT2527, a CDK9 inhibitor, and PRT-SCA2, a SMARCA2 protein degrader.

Investor Contact:
Stacey Jurchison
Executive Director, Corporate Affairs
sjurchison@preludetx.com

Melissa Forst
Argot Partners
212.600.1902
prelude@argotpartners.com

Media Contact:
Deborah Elson
Argot Partners
212.600.1902
prelude@argotpartners.com

FAQ

When is Prelude Therapeutics participating in the Morgan Stanley 19th Annual Global Healthcare Conference?

Prelude Therapeutics will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021, at 11:45 a.m. ET.

What is the schedule for Prelude Therapeutics at the H.C. Wainwright 23rd Annual Global Investment Conference?

Prelude Therapeutics will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 a.m. ET.

Where can I access the webcasts of Prelude Therapeutics' investor conferences?

The live webcasts for Prelude Therapeutics' conferences can be accessed under 'Events & Presentations' on their investor website.

What are the lead product candidates of Prelude Therapeutics?

Prelude Therapeutics' lead product candidates include PRT543, PRT811, and PRT1419, targeting advanced solid tumors and hematologic malignancies.

Who can I contact for more information about Prelude Therapeutics?

For more information, you can contact Stacey Jurchison, Executive Director of Corporate Affairs at Prelude Therapeutics.